Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karin B Olson

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Anticancer Research|June 3, 2006
Prostate cancer presenting as visual changesKarin B Olson, Kenneth J Pienta
Oncology (Williston Park, N.Y.)|December 3, 1999
Pain management in patients with advanced prostate cancerKarin B Olson Pa-C, Kenneth J Pienta
Anticancer Research|August 17, 2005
Proptosis and decreased vision secondary to prostate cancer orbital wall metastasisAsmita R Patel, Karin B Olson, Kenneth J Pienta
Urology|September 6, 2005
Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acidKarin B Olson, C Michael Hellie, Kenneth J Pienta
Journal of Cellular Biochemistry|July 1, 2005
A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactionsRobert D Loberg, Bishoy A Gayed, Karin B Olson, et al.
American Journal of Clinical Oncology|February 4, 2014
Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation TherapyJeffrey M Vainshtein, Matthew Schipper, Sean Vance, et al.
Urology|February 8, 2006
Clonality of sarcomatous and carcinomatous elements in sarcomatoid carcinoma of the prostateMichael E Ray, Kirk J Wojno, Neal S Goldstein, et al.
Urology|January 30, 2004
Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancerRobert D Loberg, Jeffery R Fielhauer, Brian A Pienta, et al.
International Journal of Radiation Oncology, Biology, Physics|April 16, 2011
Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablationAaron Sabolch, Felix Y Feng, Stephanie Daignault-Newton, et al.
Clinical Genitourinary Cancer|July 25, 2007
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinomaNiklas J Mackler, Kenneth J Pienta, Rodney L Dunn, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Anticancer Research|June 3, 2006
Prostate cancer presenting as visual changesKarin B Olson, Kenneth J Pienta
Oncology (Williston Park, N.Y.)|December 3, 1999
Pain management in patients with advanced prostate cancerKarin B Olson Pa-C, Kenneth J Pienta
Anticancer Research|August 17, 2005
Proptosis and decreased vision secondary to prostate cancer orbital wall metastasisAsmita R Patel, Karin B Olson, Kenneth J Pienta
Urology|September 6, 2005
Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acidKarin B Olson, C Michael Hellie, Kenneth J Pienta
Journal of Cellular Biochemistry|July 1, 2005
A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactionsRobert D Loberg, Bishoy A Gayed, Karin B Olson, et al.
American Journal of Clinical Oncology|February 4, 2014
Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation TherapyJeffrey M Vainshtein, Matthew Schipper, Sean Vance, et al.
Urology|February 8, 2006
Clonality of sarcomatous and carcinomatous elements in sarcomatoid carcinoma of the prostateMichael E Ray, Kirk J Wojno, Neal S Goldstein, et al.
Urology|January 30, 2004
Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancerRobert D Loberg, Jeffery R Fielhauer, Brian A Pienta, et al.
International Journal of Radiation Oncology, Biology, Physics|April 16, 2011
Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablationAaron Sabolch, Felix Y Feng, Stephanie Daignault-Newton, et al.
Clinical Genitourinary Cancer|July 25, 2007
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinomaNiklas J Mackler, Kenneth J Pienta, Rodney L Dunn, et al.
Pageof 2